Effects of CNI-1493 on human granulocyte functions

Hana Abdalla1, Tony Forslund, Thomas Schön

  • 1Department of Molecular and Clinical Medicine, Division of Medical Microbiology, Faculty of Health Sciences, Linköping University, S-581 85 Linköping, Sweden. hanab@imk.liu.se

Immunobiology
|March 15, 2006
PubMed

Insights

CNI-1493, a macrophage deactivator, reduces nitric oxide (NO) production in macrophages and alters granulocyte function. These effects may explain its survival benefits in bacterial infections like Haemophilus influenzae type b (Hib).

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Nitric oxide (NO) and inflammatory mediators are key in bacterial infections like sepsis and meningitis.
  • CNI-1493, a macrophage deactivator, previously reduced mortality in infant rats infected with Haemophilus influenzae type b (Hib).

Purpose of the Study:

  • To investigate the in vitro effects of CNI-1493 on granulocytes and macrophages.

Main Methods:

  • Murine macrophages (RAW 264.7) were pre-incubated with CNI-1493 before activation with lipopolysaccharide (LPS)/interferon gamma (IFNgamma).
  • Granulocyte function was assessed after CNI-1493 treatment and stimulation with formylmethionyl-leucyl-phenylalanine (FMLP).
  • Nitrite/nitrate levels and inducible NO-synthase (iNOS) expression were measured in macrophages.
  • Reactive oxygen species (ROS) production, F-actin content, motility, and chemotaxis were measured in granulocytes.

Main Results:

  • CNI-1493 decreased NO production and iNOS expression in activated macrophages.
  • CNI-1493 increased ROS production in FMLP-stimulated granulocytes.
  • CNI-1493 decreased F-actin content, motility, and chemotaxis in granulocytes.

Conclusions:

  • CNI-1493's effects on macrophage NO production and granulocyte function may contribute to reduced inflammation and improved survival in Hib-infected animals.
  • These findings elucidate the mechanisms underlying CNI-1493's therapeutic potential in bacterial infections.